

Challenge

A registrational Phase 3 study aimed at preventing COVID-19 in severely immunocompromised adults faced major barriers to enrollment. Patients too sick, isolated, or medically fragile to safely travel to traditional research sites severely limited study access, putting enrollment timelines at risk.

Solution

Science 37 deployed its Direct-to-Patient Site to overcome access challenges. A prescreening registry quickly identified and qualified eligible immunocompromised patients. The team enabled at-home delivery of blinded biologic medication with temperature monitoring and IV administration. Dual-nurse teams in full PPE conducted in-home assessments within 48 hours of symptom onset, while PRN rescue medications were delivered with real-time oversight from a remote Science 37 investigator. This approach successfully enrolled a geographically and culturally diverse population unreachable through traditional site selection.

Science 37 Results

Enrolled

42%

of Immunocompromised Cohort
across 36 States in 8 Weeks

>90%

Visit Completion Rate
across 700+ In-Home Visits

**Top
Enrolling
Site**

Among 95 Sites

23%

Minority Representation
Black, Asian, Hispanic



Scan to Learn More about Our Direct-to-Patient Site.

© 2025 Science 37. All rights reserved. This material is confidential and proprietary to Science 37 and shall not be distributed, edited or modified in any way without Science 37's advance written consent.

www.science37.com



**The First & Only FDA-Inspected
Direct-to-Patient Site**